Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

• Main Authors: C. Orkin, E. Dejesus, H. Khanlou, A. Stoehr, K. Supparatpinyo, E. Lathouwers, E. Lefebvre, M. Opsomer, T. Van de Casteele, F. Tomaka
• Format: Journal
• Published: 2018
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84870533547&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/48353
• Institution: Chiang Mai University

Objective: This paper presents the final analysis of once-daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment-naïve HIV-1-infected adults. Methods: ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In naïve Subjects; NCT00258557) was a randomized, open-label, phase-III,...